Sign Up Today and Learn More About Rapport Therapeutics Stock
Invest in or calculate the value of your shares in Rapport Therapeutics or other pre-IPO companies through EquityZen's platform.
Rapport Therapeutics Stock (RAPT)
Rapport Therapeutics is a clinical-stage biotechnology company that discovers and develops precision medicines for neurological disorders.
About Rapport Therapeutics Stock
Founded
2022
Headquarters
Boston, MA, US
Industries
Sports, Software, Artificial Intelligence
Rapport Therapeutics Press Mentions
Stay in the know about the latest news on Rapport Therapeutics
RAPP: Global phase III epilepsy trials advance with robust data and broad commercial potential
tradingview • Jun 08, 2026
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
globenewswire • May 07, 2026
Rapport Therapeutics, Inc. 1Q 2026: Revenue $20M, EPS $(0.42) — 10-Q Summary
tradingview • May 07, 2026
Rapport Therapeutics presents RAP-219 focal onset seizure phase 2a follow-up period results
marketscreener • Apr 23, 2026
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
biospace • Apr 02, 2026
Rapport Therapeutics Management
Leadership team at Rapport Therapeutics
Director
Sanjay Mistry
Board Member
Steven Paul
Join now and verify your accreditation status to gain access to:
- Rapport Therapeutics Current Valuation
- Rapport Therapeutics Stock Price
- Rapport Therapeutics Management
- Available deals in Rapport Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Rapport Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Rapport Therapeutics Revenue and Financials
- Rapport Therapeutics Highlights
- Rapport Therapeutics Business Model
- Rapport Therapeutics Risk Factors
- Rapport Therapeutics Research Report from SACRA Research
Trading Rapport Therapeutics Stock
How to invest in Rapport Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Rapport Therapeutics through EquityZen funds. These investments are made available by existing Rapport Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Rapport Therapeutics stock?
Shareholders can sell their Rapport Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 54K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
